News
U.S. stock indexes inched their way to more records Monday to kick off a week full of profit updates from big U.S. companies.
U.S. stock indexes inched their way to more records on Monday to kick off a week full of profit updates from big U.S.
U.S. stock indexes inched to more records to kick off a week full of profit updates from big U.S. companies. The S&P 500 rose ...
U.S. stock indexes inched their way to more records on Monday to kick off a week full of profit updates from big U.S.
U.S. stock indexes inched their way to more records on Monday to kick off a week full of profit updates from big U.S. compan ...
Asian shares are mixed and U.S. futures have edged higher after U.S. stocks logged their third straight winning week.
17h
InvestorsHub on MSNSarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular DystrophyShares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...
Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review ...
On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or ...
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a second death linked to its Duchenne muscular dystrophy gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results